ХИМИОТЕРАПИЯ НЕОПЕРАБЕЛЬНОГО РАКА ЖЕЛЧЕВЫВОДЯЩИХ ПРОТОКОВ. ОБЗОР

Библиографические ссылки:

Surya H., Abdullah M., Nelwan E.J., et al. Current Updates on Diagnosis and Management of Cholangiocarcinoma: from Surgery to Targeted Therapy. Acta Med Indones. 2023; 55(3): 361-370.

Peirce V., Paskow M., Qin L., et al. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer. Target Oncol. 2023; 18(6): 837-852.https://doi.org/10.1007/s11523-023-01000-5

Состояние онкологической помощи населению России в 2020 году / под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой – М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2021. – 239 с.

Общероссийский национальный союз «Ассоциация онкологов России». Рак желчевыводящей системы. Клинические рекомендации. 2020. 51 с. Ссылка активна на 23.03.2023. https://oncology-association.ru/wp-content/uploads/2020/09/biliarnyj_rak.pdf

Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klumpen H.J., Malka D., et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(2): 127-40.https://doi.org/10.1016/j.annonc.2022.10.506

Trifylli E.M., Kriebardis A.G., Koustas E., et al. The Arising Role of Extracellular Vesicles in Cholangiocarcinoma: A Rundown of the Current Knowledge Regarding Diagnostic and Therapeutic Approaches. Int J Mol Sci. 2023; 24(21): 15563.https://doi.org/10.3390/ijms242115563

Zhao D.Y., Lim K.H. Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol. 2017; 8(3): 430-40.https://doi.org/10.21037/jgo.2017.05.04

Baria K., De Toni E.N., Yu B., Jiang Z., Kabadi S.M., Malvezzi M. Worldwide incidence and mortality of biliary tract cancer. Gastro Hep Adv. 2022; 1(4): 618-26.https://doi.org/10.1016/j.gastha.2022.04.007

Zamani Z., Fatima S. Biliary tract cancer. Treasure Island: Stat Pearls; 2021.

Chоlеstаtic Jаundicе / R. Shаh, S. Jоhn // In: StаtPеаrls Intеrnеt. Trеаsurе Islаnd (FL): StаtPеаrls Publishing. 2022. – PMID: 29489239.

Nakachi K., Gotohda N., Hatano E., Nara S., Takahashi S., Kawamoto Y., Ueno M. Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials. Jpn J Clin Oncol. 2023 Nov 5; 53(11): 1019-1026.https://doi.org/10.1093/jjco/hyad103.. PMID: 37599063

Oh D.Y., He A.R., Qin S., Chen L.T., Okusaka T., Vogel A., et al. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer. Future Oncol. 2023 Nov; 19(34): 2277-2289.https://doi.org/10.2217/fon-2023-0468.. Epub 2023 Sep 25. PMID: 37746835.

Shin D.W. Treatment of Ampullary Adenocarcinoma. Korean J Gastroenterol. 2023 Oct 25; 82(4): 159-170. Korean.https://doi.org/10.4166/kjg.2023.110.. PMID: 37876255

Fung S., Syed Y.Y. Durvalumab: A Review in Advanced Biliary Tract Cancer. Target Oncol. 2023 Nov 9.https://doi.org/10.1007/s11523-023-01007-y..

Oh D-Y., Ruth He A., Qin S., Chen L-T., Okusaka T., Vogel A., et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022; 1(8): EVIDoa2200015.https://doi.org/10.1056/EVIDoa2200015

Bekaii-Saab T.S., Valle J.W., Van Cutsem E., Rimassa L., Furuse J., Ioka T., et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020; 16(30): 2385-2399. https://doi.org/10.2217/fon-2020-0429

Hyung J., Kim B., Yoo C., Kim K.P., Jeong J.H., Chang H.M., et al. Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin. Cancer Res Treat. 2019; 51(3): 901-909.https://doi.org/10.4143/crt.2018.326

Shin D.W., Kim M.J., Lee J.C., Kim J., Woo S.M., Lee W.J., et al. Gemcitabine plus cisplatin chemotherapy prolongs the survival in advanced hilar cholangiocarcinoma: a large multicenter study. Am J Clin Oncol. 2020; 43(6): 422-427. https://doi.org/10.1097/COC.0000000000000682

Cheon J., Lee C.K., Sang Y.B., Choi H.J., Kim M.H., Ji J.H., et al. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. Ther Adv Med Oncol. 2021; 13. https://doi.org/10.1177/17588359211035983

Salati M., Caputo F., Cunningham D., Marcheselli L., Spallanzani A., Rimini M., et al. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. Eur J Cancer. 2019; 117: 84-90.https://doi.org/10.1016/j.ejca.2019.05.030

Kelley R.K., Ueno M., Yoo C., Finn R.S., Furuse J., Ren Z., et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10391): 1853-1865.https://doi.org/10.1016/S0140-6736(23)00727-4

Zhang Z., Wang X., Li H., Sun H., Chen J., Lin H. Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review. Front Immunol. 2023 Aug 21; 14: 1230261.https://doi.org/10.3389/fimmu.2023.1230261.. PMID: 37671157; PMCID: PMC10475830.

US Food and Drug Administration. FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locally advanced or metastatic biliary tract cancer. 2022. Available from:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-imfinzi-durvalumab-adult-patients-locally-advanced-or#:~:text=On%20September%202%2C%202022%2C%20FDA,or%20metastatic%20biliary%20tract%20cancer.or%20metastatic%20biliary%20tract%20cancer. Accessed 21 Apr 2023.

Jiang Y., Zeng Z., Zeng J., Liu C., Qiu J., Li Y., et al. Efficacy and safety of first-line chemotherapies for patients with advanced biliary tract carcinoma: a systematic review and network meta-analysis. Front Oncol. 2021; 11: 736113.https://doi.org/10.3389/fonc.2021.736113

Wiazzane N., Chauffert B., Ghiringhelli F. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2013; 37(6): 614-618.https://doi.org/10.1016/j.clinre.2013.03.003

You M.S., Ryu J.K., Choi Y.H., Choi J.H., Huh G., Paik W.J.H., et al. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin. BMC Cancer. 2019; 19(1): 10.https://doi.org/10.1186/s12885-018-5211-y

Ulusakarya A., Karaboué A., Ciacio O., Pittau G., Haydar M., Biondani P., et al. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer. 2020; 20(1): 515. https://doi.org/10.1186/s12885-020-07004-y

Zheng-Lin B., Graham R.P., Bekaii-Saab T.S. Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers. Chin Clin Oncol. 2023 Oct; 12(5): 55.https://doi.org/10.21037/cco-23-72.. PMID: 37964543.

Xing P., Wang S., Cao Y., Liu B., Zheng F., Guo W., Huang J., Zhao Z., Yang Z., Lin X., Sang L., Liu Z. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs. Drug Resist Updat. 2023 Aug 22; 71: 101002.https://doi.org/10.1016/j.drup.2023.101002.. Epub ahead of print. PMID: 37678078.

Jansen H., Pape U.F., Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol. 2020; 11(4): 770-789.https://doi.org/10.21037/jgo-20-203

Benson A.B., D'Angelica M.I., Abrams T., Abbott D.E., Ahmet A., Anaya D.A., et al. Biliary tract cancers, version 1.2023, NCCN clinical practice guidelines in oncology. 2023. Available from:https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517.. Accessed 21 Apr 2023.

Ghidini M., Pizzo C., Botticelli A., Hahne J.C., Passalacqua R., Tomasello G., et al. Biliary tract cancer: current challenges and future prospects. Cancer Manag Res. 2019; 11: 379-388.https://doi.org/10.2147/CMAR.S157156

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). 2022. Available from:https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.. Accessed 6 Dec 2022.

Alberta Health Services. Cholangiocarcinoma and gallbladder cancer. 2019. Available from:https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gi010-biliary.pdf.. Accessed 12 Jan 2023.

Gotfrit J., Goodwin R., Asmis T., Hyde A.J., Alcindor T., Aubin F., et al. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. Curr Oncol. 2021; 28(3): 1988-2006.https://doi.org/10.3390/curroncol28030185

Abou-Alfa G.K., Macarulla T., Javle M.M., et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6): 796-807.https://doi.org/10.1016/S1470-2045(20)30157-1

Zhu A.X., Macarulla T., Javle M.M., et al. Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021; 7(11): 1669-77.https://doi.org/10.1001/jamaoncol.2021.3836

Javle M., Borad M.J., Azad N.S., et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021; 22(9): 1290-300.https://doi.org/10.1016/S1470-2045(21)00336-3

Javle M., Roychowdhury S., Kelley R.K., et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021; 6(10): 803-15.https://doi.org/10.1016/S2468-1253(21)00196-5

Borad M.J., Bridgewater J.A., Morizane C., Shroff R.T., Oh D-Y., Moehler M.H., et al. A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3). J Clin Oncol. 2020; 38(4_Suppl.): TPS600.

Abou-Alfa G.K., Sahai V., Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21(5): 671-84.https://doi.org/10.1016/S1470-2045(20)30109-1

Chawla S.P., Wong S., Quon D., et al. Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130). Front. Mol. Med. 2022; 2: 1092286. https://doi.org/10.3389/fmmed.2022.1092286

Liu S., Chawla S.P., Bruckner H., et al. Long Term Survival Following DeltaRex-G/DeltaVax Tumor-Targeted Gene Therapy for Advanced Chemotherapy Resistant Malignancies: An Academic Milestone. Clin Oncol. 2021; 6: 1807.

Wang J., Xue Y., Liu R., Wen Z., Ma Z., Yang X., Yu L., Yang B., Xie H. DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study. Front Bioeng Biotechnol. 2023; 10: 1112500.https://doi.org/10.3389/fbioe.2022.1112500

Yuan P., Song J., Wang F., Zhu G., Chen B. Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. Invest New Drugs. 2023; 41(1): 182.https://doi.org/10.1007/s10637-022-01323-6

He M., Jiang N., Yin X., Xu A., Mu K. Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. J Cancer Res Clin Oncol. 202; 149(1): 531-540.https://doi.org/10.1007/s00432-022-04485-1

Ning Z., Xie L., Yan X., Hua Y., Shi W., Lin J., Xu L., Meng Z. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. Br J Radiol. 2023; 96(1150): 20230079.https://doi.org/10.1259/bjr.20230079

Zhang H., Han C., Zheng X., Zhao W., Liu Y., Ye X. Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review. J Cancer Res Ther. 2023; 19(4): 1055-1060.https://doi.org/10.4103/jcrt.jcrt_1697_22.. PMID: 37675736.

Young S., Torkian P., Flanagan S., D'Souza D., Sanghvi T., Golzarian J. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization. J Gastrointest Oncol. 2023; 14(5): 2202-2211.https://doi.org/10.21037/jgo-23-210

White J., Carolan-Rees G., Dale M., Patrick H.E., See T.C., Bell J.K., et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational Study. J Vasc Interv Radiol. 2019; 30(8): 1185-1192.https://doi.org/10.1016/j.jvir.2019.03.018

Schaarschmidt B.M., Kloeckner R., Dertnig T., Demircioglu A., Müller L., Auer T.A., Santos D.P.D., Steinle V., Miederer M., Gebauer B., Radunz S., Kasper S., Weber M., Theysohn J. Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by 90Y Radioembolization: A Multicenter Retrospective Study. J Nucl Med. 2023; 64(4): 529-535.https://doi.org/10.2967/jnumed.122.264598

Owen M., Makary M.S., Beal E.W. Locoregional Therapy for Intrahepatic Cholangiocarcinoma. Cancers (Basel). 2023; 15(8): 2384.https://doi.org/10.3390/cancers15082384

Auer T.A., Collettini F., Segger L., Pelzer U., Mohr R., Krenzien F., Gebauer B., Geisel D., Hosse C., Schöning W., Fehrenbach U. Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma. Cancers (Basel). 2023; 15(9): 2655.https://doi.org/10.3390/cancers15092655

Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021; 134: 178-189. https://doi.org/10.1016/j.jclinepi.2021.03.001

Müller L., Mähringer-Kunz A., Jungmann F., Tanyildizi Y., Bartsch F., Czauderna C., et al. Risk stratification in advanced biliary tract cancer: validation of the A.L.A.N. score. J Oncol. 2020. https://doi.org/10.1155/2020/6180613

Beaulieu C., Lui A., Yusuf D., Abdelaziz Z., Randolph B., Batuyong E., et al. A population-based retrospective study of biliary tract cancers in Alberta, Canada. Curr Oncol. 2021; 28(1): 417-427.https://doi.org/10.3390/curroncol28010044

Koch C., Franzke C., Bechstein W.O., Schnitzbauer A.A., Filmann N., Vogl T., et al. Poor prognosis of advanced cholangiocarcinoma: real-world data from a tertiary referral center. Digestion. 2020; 101(4): 458-465. https://doi.org/10.1159/000500894.

Gonzalez-Carmona M.A., Bolch M., Jansen C., Vogt A., Sampels M., Mohr R.U., et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Aliment Pharmacol Ther. 2019; 49(4): 437-447.https://doi.org/10.1111/apt.15050..